On Jun. 20, 2014, the U.S. Centers for Disease Control and Prevention (CDC) published Immunization Practices Advisory Committee (ACIP) recommendations for use of MenACWY-CRM vaccine in children age 2-23 months at increased risk for meningococcal disease.

MenACWY-CRM is the first quadrivalent meningococcal conjugate vaccine licensed for use in children aged 2 through 8 months.